Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B. Chapman
, Axel Hauschild
, Caroline Robert
, John B. Haanen
, Paolo Ascierto
, James Larkin
, Reinhard Dummer
, Claus Garbe
, Alessandro Testori
, Michele Maio
, David Hogg
, Paul Lorigan
, Celeste Lebbe
, Thomas Jouary
, Dirk Schadendorf
, Antoni Ribas
, Steven J. O'Day
, Jeffrey A. Sosman
, John M. Kirkwood
,
Alexander M.M. Eggermont
Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
Show 8 more
Show less
Research output
:
Contribution to journal
›
Article
›
peer-review
6896
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
95% Confidence Interval
20%
Adverse Events
10%
Alopecia
10%
Arthralgia
10%
Body Surface Area
10%
BRAF V600E mutation
100%
Dacarbazine
60%
Data Monitoring
10%
Diarrhea
10%
Disease Progression
10%
Dose Adjustment
10%
Duration of Response
10%
Improved Survival
100%
Interim Analysis
30%
Keratoacanthoma
10%
Melanoma
100%
Metastatic Melanoma
20%
Monitoring Boards
10%
Nausea
10%
Overall Survival
20%
Phase 1 Clinical Trial
10%
Phase I Trial
10%
PLX4032
10%
Previously Untreated
20%
Progression-free Survival
30%
Raf Kinase Inhibitor Protein
10%
Randomized Clinical Trial
10%
Rash
10%
Relative Reduction
10%
Response Rate
40%
Risk of Death
10%
Safety Monitoring
10%
Squamous Cell Carcinoma (SqCC)
10%
Toxic Effects
10%
Twice Daily
10%
Vemurafenib
100%
Medicine and Dentistry
Adverse Event
9%
Alopecia Mucinosa
9%
Arthralgia
9%
B Raf Kinase Inhibitor
9%
Body Surface
9%
Clinical Trial
9%
Dacarbazine
54%
Diarrhea
9%
Disease Exacerbation
9%
Exanthem
9%
Interim Analysis
27%
Keratoacanthoma
9%
Melanoma
100%
Metastatic Melanoma
18%
Nausea
9%
Overall Survival
18%
Photosensitivity
9%
Progression Free Survival
27%
Randomized Clinical Trials
9%
Squamous Cell Carcinoma
9%
Vemurafenib
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Alopecia
9%
Arthralgia
9%
B Raf Kinase Inhibitor
9%
Clinical Trial
9%
Dacarbazine
54%
Diarrhea
9%
Disease Exacerbation
9%
Keratoacanthoma
9%
Melanoma
100%
Metastatic Melanoma
18%
Nausea
9%
Overall Survival
18%
Photosensitivity
9%
Progression Free Survival
27%
Randomized Clinical Trial
9%
Rash
9%
Squamous Cell Carcinoma
9%
Vemurafenib
100%